AI Article Synopsis
- Acute kidney injury (AKI) is a serious medical condition characterized by reduced kidney function, leading to issues like nitrogen retention and electrolyte imbalances, with high mortality rates (5-80%) in ICU patients.
- Current treatments focus on addressing the underlying cause and maintaining balance in body fluids, but no effective overall therapy exists yet.
- Recent studies have highlighted the potential of Astragalus, particularly its active component astragaloside IV, in treating AKI within the framework of traditional Chinese medicine.
Article Abstract
Acute kidney injury (AKI) is one of the most common clinical critical illnesses, with decreased glomerular filtration rate, retention of nitrogen products, water and electrolyte disorders, and acid-base imbalance as the main clinical manifestations. Presently, there is no effective treatment for acute kidney injury, but the main treatment is to cure the primary disease, remove risk factors, maintain acid-base and water-electrolyte balance, and undergo kidney replacement. However, the mortality rate is still high. Investigations and studies showed that the mortality rate of patients with acute kidney injury in the ICU is 5-80% [1]. In recent years, Chinese medicine has been widely used in acute kidney injury treatment due to its complete dialectical system and rich experience. Astragalus is a commonly used medicine in traditional Chinese medicine to treat acute kidney injury. Astragaloside IV is the main active component of traditional Chinese medicine, Astragalus membranaceus. This article summarizes the relevant studies on treating acute kidney injury with astragaloside IV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-024-04016-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!